Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Partial nephrectomy is even more critical in early-onset RCC

Clemmensen T et al. Human Pathology April 2018 25-31. https://doi.org/10.1016/j.humpath.2017.11.005

Key clinical point: Patients who develop RCC before age 47 typically have comorbidities that place them at an increased risk for chronic kidney disease and end-stage renal disease. Partial nephrectomy is even more critical to pursue if deemed feasible in this at-risk population. Only 2/96 (2.1%) patients in the early onset RCC group had disease recurrence.

Major finding: Compared to the control group, early onset RCC patients were more likely to undergo a partial nephrectomy (P = .002) and 78% of patients presented with stage 1a (52/91) or 1b (19/91) disease. In the control group, 67% of patients presented with stage 1a (234/500) or 1b (101/500) disease. In the early onset RCC group, 9/91 (9.9%) patients presented with stage 3 disease, compared to 120/500 (24%) patients in the control group.

Study details: A retrospective search of a surgical pathology database performed from 2011 to 2016 identified 598 RCCs in 576 patients. In the early onset RCC group, 98 (16.4%) RCCs occurred in 96 patients. The remaining 500 (83.6%) RCCs occurred in 480 patients older than 46 years, which comprised the control group.

Disclosures: The researchers had no relevant financial disclosures.

Source: Clemmensen T et al. Human Pathology April 2018 25-31. https://doi.org/10.1016/j.humpath.2017.11.005

Citation:

Clemmensen T et al. Human Pathology April 2018 25-31. https://doi.org/10.1016/j.humpath.2017.11.005

This Week's Must Reads

Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019

Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055

Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022

High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.

Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Must Reads in Renal Cell Carcinoma

In mRCC: Sunitinib alone not inferior to nephrectomy-sunitinib, Méjean A et al. N Engl J Med. 2018 Aug 2. doi: 10.1056/NEJMoa1803675.

Proactive management eases side effects of sunitinib treatment in RCC, Staehler M et al. Ann Oncol. 2018 Aug 23. doi: 10.1093/annonc/mdy329

Red cell distribution width might predict cancer-specific survival in RCC , Życzkowski M et al. Clinical Genitourinary Cancer 2018 June (16), e677-e683. https://doi.org/10.1016/j.clgc.2017.12.003

mRCC: Patients survive longer at high-volume centers, Joshi SS et al. Euro Urol. 2018 Sep;74[3]:387-93.

High PD1 mRNA levels tied to anti-PD1 monotherapy response, Paré L et al. Ann Oncol. 2018 Aug 27. doi: 10.1093/annonc/mdy335.